ENTX
Entera Bio Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.94
+9.70%Year over year
Reported trailing growth
- Revenue
- -100.0%
- EBITDA
- -35.2%
- EBIT
- -36.0%
- EPS
- —
- Free cash flow
- -70.3%
- Operating cash flow
- -70.1%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- -29.8%
Three-year CAGR
- Revenue
- -32.1%
- EBITDA
- -20.3%
- EBIT
- -20.3%
- Net income
- -19.9%
- EPS
- +0.0%
- Free cash flow
- -9.6%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026